FDA Approves Atacand for Use with an ACE Inhibitor in the Treatment of Heart Failure

... AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new use for its angiotensin receptor blocker (ARB) ATACAND (candesartan cilexetil) tablets for the treatment of heart failure (NYHA class II-IV) in patients with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations... click link for more info. ...